Multidisciplinary Association For Psychedelic Studies

Meet Oregon's Legal Psilocybin Retreats Powered By NASA And Ivy League Talent
NFL's Jon Feliciano Takes His Psychedelics Advocacy To The Field: Chooses MAPS As His "My Cleats, My Cause"
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
NFL's Jon Feliciano Takes His Psychedelics Advocacy To The Field: Chooses MAPS As His "My Cleats, My Cause"
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Burning Man CEO Learned 'So Much' About Psychedelics In BRC: 'We're Here For The Love'

Multidisciplinary Association For Psychedelic Studies Recent News

Gov. Polis To Open MAPS' Psychedelic Science 2023 Event Where 2 New Shulgin Compounds Will Be Revealed
Psychedelic Science, this year’s gathering hosted by the legendary nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced its final agenda, which will include opening remarks by Colorado Governor Jared Polis, featured speakers and a new local day-pass option.
The Flaming Lips, Eric Andre, Reggie Watts And Many More At MAPS 2023 Psychedelic Event
MAPS’ Psychedelic Science 2023 is taking place this June in Denver.
MDMA Therapy For PTSD Nearing Legalization In US And Worldwide, MAPS Releases Promising Data
Zinger Keypoints: Long-term (over 1 year) follow-up reflects lasting improvements in symptom severity. Data confirms prior Phase 2 studies on MDMA-assisted therapy’s sustained effect on PTSD treatment.
Psychedelic Science 2023: Details On Agenda And Acclaimed Speakers At MAPS Annual Gathering
The historical non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) has announced the agenda and featured speakers of its Psychedelic Science 2023 conference taking place June 19-25, 2023 in Denver, Colorado, organized by Momentum Events.
Women's Footprint In Psychedelics Is Undeniable, Benzinga's Psychedelics Advisory Council's Six New Trailblazers
In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council.
Palo Santo Closes $50M Psychedelic Therapeutics Investment Fund
Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million fund.
MAPS Gets A New Partner To Study MDMA Therapy In Patients With PTSD
In recent months, the psychedelics space has been ground for increasing collaborations. In some cases it was to advance scientific studies.
Patents In The Psychedelics Space: Good Or Bad? It's Complicated, Here's What The Experts Say
Patents are the golden eggs of the booming psychedelic space.
Ecstasy Research Trial Completes Enrollment, Moves Closer To Approval To Treat PTSD
The non-profit Multidisciplinary Association for Psychedelics Studies (MAPS) and its subsidiary MAPS Public Benefit Corporation finished the enrollment stage for the second Phase 3 clinical trial on MDMA (MAPP2).
DEA Under Fire For Blocking Psilocybin As Treatment For Terminally Ill Cancer Patients
The Drug Enforcement Administration (DEA) will face activists at its headquarters in Arlington, Virginia, reported Mary-Elizabeth Gifford and Justin Grant of Lucid News. Protestors intend to block the entrance to the building to call attention to the rights
Numinus Administers MDMA To First Volunteer In Clinical Trial Sponsored By MAPS
Psychedelic Companies Keenly Aware Of Creating Therapies As Healthcare Reimbursement Possibility Looms
In the quest to design effective and affordable psychedelic treatments for a range of maladies that include PTSD and depression, one key thought on the minds of company executives and clinicians alike seems to be how to motivate healthcare insurance companies to cover the cost of psychedelic therapies.
Australian Psychiatrist Sues State Of Victoria For Denying MDMA Treatment For Ailing Patient
The Australian state of Victoria faces a seminal lawsuit that seeks to make MDMA available for severe mental illness.
Can MDMA Treat Traumatic Brain Injury? $1.5 Million Are Being Committed To Finding Out
Wesana Health (CSE: WESA) (OTCQB: WSNAF) and the Multidisciplinary Association for Psychedelic Studies (MAPS) are teaming up to analyze the effectiveness of MDMA-assisted therapy in the treatment of traumatic brain injury (TBI).
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha. In just a couple of years, psychedelics took the world of investing by storm.
World's First Phase 3 Clinical Trial On MDMA Shows 'Powerful New Pathway To Healing'
The results from the world’s first Phase 3 clinical study on a psychedelic are in — and they’re significant. The Multidisciplinary Association for Psychedelic Studies released the results from its Phase 3 trial on MDMA for the treatment of post-traumatic stress disorder. 
What Will The Psychedelics Space Look Like In 2021? Experts Weigh In
In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed. 
Psyched: NeonMind, Novamind Go Public; MAPS And Field Trip Study MDMA, Psychedelics Center Launches In NYC
NeonMind Goes Public Psychedelics biotech company NeonMind debuted on the Canadian Securities Exchange (CSE) Monday under the symbol ‘NEON.’
2020 Was The Year of Psychedelics — Here's Why
While many 2020 memories will be gladly left behind, that's not necessarily the case for psychedelics. There was unprecedented renaissance as psychedelic compounds, and their potential to treat mental health conditions, became one of the centerpieces of this year’s public conversation. 
Psyched: Numinus, MAPS To Spearhead MDMA Trials; Vancouver Plans To Decriminalize Drugs
Numinus and MAPS Collaborate to Study MDMA in Canada Numinus Wellness (TSXV: NUMI) and the MAPS Public Benefit Corporation have joined forces to bring MDMA-assisted psychotherapy through clinical trials for approval in Canada.
ATAI Launches Subsidiary To Develop MDMA Derivatives
Psychedelics and biotech company ATAI Life Sciences announced on Monday the launch of a new subsidiary that will focus on the development of MDMA derivatives for the treatment of post-traumatic stress disorder and other indications. EmpathBio will be a wholly owned subsidiary of ATAI, led by CEO Glenn Short.
'Psyched': MAPS Scores $30M, Mydecine Gets Psilocybin License, Psychedelic Science Sold
MAPS Gets $30M In Funds To Conclude MDMA Research